Pfizer has announced that as apart of global research facility strategy under Wyeth merger, will close six sites including New London facility. The staff froms New London facility be transitioned to Groton, CT.
The company will concentrate its research laboratory in five sites across La Jolla, CA; Sandwich, England, Cambridge, MA; Groton, CT; and Pearl River, NY.
Pfizer has confirmed that it will shut down R&D operations in Princeton, NJ; Chazy, NY; Rouses Point, NY; and Plattsburgh, NY; Sanford, NC and Research Triangle Park, NC; and Gosport, England and Slough/Taplow, England.
Martin Mackay, president of research & development at Pharma Therapeutics, said: “In less than a month, we have made complex business decisions needed to combine these two R&D organisations thoughtfully yet quickly. Moving forward on our aggressive timeline, we are analysing the combined portfolio and prioritising research projects that will address unmet medical need and bring Pfizer’s scientific and competitive advantage to the benefit of patients.
“In Groton and New London, there will be a minimal headcount effect. Our presence in Connecticut will be approximately the same … it’s about 5,000 now, and that number will continue, though the makeup will change around the edges.”